GTx-007 (S-4) 是具有口服活性的、選擇性的非甾體受體雄激素受體 (AR) 調(diào)節(jié)劑 (SARM) 和部分激動劑，Ki為4 nM。GTx-007 (S-4) 是具有較強活性的、具有組織選擇性的 SARM。

GTx-007 (S-4) is only a partial agonist in the prostate and seminal vesicles, restoring them to 33.8 and 28.2% of intact animals, respectively[2].
GTx-007 significantly increased uterine expression of Wnt4 and Wnt7a[2].

Resulted in a highly heterogeneous pattern of AR expression in all compartments, with a significant increase of AR-positive cells in the luminal epithelium compared to VC.
Had approximately ten glands per uterine cross-section within an endometrium, with a compact stroma, consistent with overall endogenous steroid depletion.
Did not detect any impact of GTx-007 on body weight.